The novel non-conventional metallodrug [(η6-p-cymene)2Ru2mitoxantronato]Cl2 (1) exhibits redox activity, DNA intercalation ability, cathepsin B and D inhibition and in vitro antitumor activity able to circumvent cisplatin resistance. Moreover, 1 can be successfully incorporated into MIL100(Fe) as a proof of concept of the feasibility of metal–organic frameworks as carriers of non-conventional drugs.
Biophysical characterisation, antitumor activity and MOF encapsulation of a half-sandwich ruthenium(ii) mitoxantronato system / S. Rojas, E. Quartapelle Procopio, F.J. Carmona, M.A. Romero, J.A.R. Navarro, E. Barea. - In: JOURNAL OF MATERIALS CHEMISTRY. B. - ISSN 2050-750X. - 2:17(2014 Mar 18), pp. 2473-2477.
Biophysical characterisation, antitumor activity and MOF encapsulation of a half-sandwich ruthenium(ii) mitoxantronato system
E. Quartapelle ProcopioSecondo
;
2014
Abstract
The novel non-conventional metallodrug [(η6-p-cymene)2Ru2mitoxantronato]Cl2 (1) exhibits redox activity, DNA intercalation ability, cathepsin B and D inhibition and in vitro antitumor activity able to circumvent cisplatin resistance. Moreover, 1 can be successfully incorporated into MIL100(Fe) as a proof of concept of the feasibility of metal–organic frameworks as carriers of non-conventional drugs.
| File | Dimensione | Formato | |
|---|---|---|---|
|
c3tb21455a.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
415.56 kB
Formato
Adobe PDF
|
415.56 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
